Circulating KIM-1 & ctDNA as Prognostic Markers in Oligometastatic Clear Cell Renal Cell Carcinoma (ccRCC): The K-COMPASS Model

• Biomarker assay development, validation & clinical testing solutions tailored for drug programmes 
• Flexible platforms, chemistries & technologies for multiple diseases indications 
• Support for global regulatory strategies including EU (IVDR) and FDA
• Pharma Case Study: Learn how Almac has supported Global clinical studies

Speakers:

Pavlos Msaouel

Associate Professor

The University of Texas MD Anderson Cancer Center.